MedPath

Criticality Analysis of Diabetic Gait Within a Primary Care Pediatric Clinic for Obese Children (PAIDOS)

Completed
Conditions
Childhood Obesity
Interventions
Diagnostic Test: Gait analysis
Registration Number
NCT03943108
Lead Sponsor
Dr Salvador Villalpando-Carrion
Brief Summary

One of the difficulties with diabetes care is the problem of predicting progression to more severe stages using current measures (for example blood glucose, HbA1c). This feasibility study aims to use Criticality Analysis (CA) of gait to monitor the progression of the condition as well as identifying individuals at risk of developing diabetes among children in Mexico.The study will investigate whether gait analysis can be used as a fast, reliable and cost effective way to detect individuals at risk of developing Type 2 Diabetes (T2DM) as early treatment could reduce the number of cases that develop into full T2DM.

Detailed Description

This feasibility study aims to the do the following:

1. To evaluate the use of Criticality Analysis of Gait as means of Diabetes assessment.

2. To design and set up a clinical feasibility study in a hospital (Hospital Infantil de Mexico) with adolescent patients on different clinical stages of type 2 Diabetes mellitus (DM).

3. To analyse the collected data and validate Gait data analysis as mechanism for identifying and monitoring pre-diabetic teenagers.

4. To use the feasibility study conducted in Mexico to develop a robust method using Gait analysis for diabetes prevention and management.

Participants will be selected from the Primary Care Pediatric Clinic for Obese Children (PAIDOS) in the Hospital Infantil de México Federico Gómez, Mexico City, Mexico. Sixty participants will be selected and divided into three groups: 40 obese non-diabetic subjects, 10 with Type 2 Diabetes and 10 healthy subjects as controls. Obese participants within the Paidos clinic will undergo standard clinical care that includes dietary prescription of caloric intake according to height, 150 min weekly physical activity, group cognitive-behavioural intervention, 6 session of obesity awareness and educational program.

Gait will be recorded in all groups using a sensor on the 4th vertebrae of the lumbar spine, once a week across 6 weeks during the routine PAIDOS clinic. Critical changes in walking control, stride frequency and length will be observed as individuals change speed; effectively stressing their mobility. The study will be repeated after 3-6 months as a follow up.

Data analysis will be performed in a semi-blind manner in order to test the efficacy of the criticality analysis Rate control of Chaos (RCC) model. In order to provide an objective measure of analysis, the anonymised data will be presented to the nonlinear RCC models, where results can be extracted and compared afterwards to known states.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
48
Inclusion Criteria
  • BMI over 95 th percentile for age
  • Living in Major Mexico City area
Exclusion Criteria
  • Diabetic patients
  • major physical disability

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Children with Type 2 DiabetesGait analysisChjildren with Type 2 Diabetes attending the Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
Obese teenagers within the PAIDOS clinicGait analysisObese children within the PAIDOS clinic, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
Healthy childrenGait analysisHealthy children living in Mexico City, Mexico.
Primary Outcome Measures
NameTimeMethod
Gait6 weeks, 3 and 6 month post-baseline follow-up

Critical changes in walking control, stride frequency and length observed as individuals change speed using a movement sensor (Inertial Measurement Units (IMU) on the 4th vertebrae of the lumbar spine). Recorded during a 10 metre walk and 6 minute walk test

Secondary Outcome Measures
NameTimeMethod
Total cholesterol6 weeks, 3 and 6 month post-baseline follow-up

Measured in milligram/deciliter (mg/dL) of blood.

Level of High-density lipoprotein (HDL) in blood6 weeks, 3 and 6 month post-baseline follow-up

Measured in milligram/deciliter (mg/dL) of blood.

Low-density lipoprotein (LDL)6 weeks, 3 and 6 month post-baseline follow-up

Measured in milligram/deciliter (mg/dL) of blood.

Alanine aminotransferase (ALT)6 weeks, 3 and 6 month post-baseline follow-up

Measured in microUnit/milliliter (McU/mL) of blood.

Homeostatic model assessment (HOMA) Index6 weeks, 3 and 6 month post-baseline follow-up

Index that allows the re-estimation of insulin resistance and Beta cell function through glucose concentration and plasma insulin during fasting state.

Weight6 weeks, 3 and 6 month post-baseline follow-up

Kilograms (Kg)

Leg LengthBaseline- Week 1

The distance from the anterior superior iliac spine to the medial malleolus in centimetres (cm) using a tape measure.

Shoe SizeBaseline- Week 1

Mexican Shoe Size (length of foot in centimeters (cm) using a tape measure).

Physical Activity- Accelerometer6 weeks

Axivity AX3 Monitors

6 Minute Walk test (6MWT)6 weeks, 3 and 6 month post-baseline follow-up

Distance traveled during the 6MWT in metres

Respiratory rate6 weeks, 3 and 6 month post-baseline follow-up

Recorded before and after the 6MWT.

Borg scale of perceived exertion6 weeks, 3 and 6 month post-baseline follow-up

Recorded during the 6MWT

Fasting blood Glucose6 weeks, 3 and 6 month post-baseline follow-up

Level of glucose after 12 hours fasting (overnight) measured in milligram/deciliter (mg/dL) of blood.

Heart rate6 weeks, 3 and 6 month post-baseline follow-up

Number of beats per minute (BPM) recorded before and after the 6MWT. Determination by palpation of radial, brachial, carotid, or other pulse or by auscultation in precordial area using a stethoscope.

O2 saturation (mmHg) using a pulse Oximeter6 weeks, 3 and 6 month post-baseline follow-up

Recorded before and after the 6MWT.

Blood Pressure (mmHg) using a baumanometer6 weeks, 3 and 6 month post-baseline follow-up

Recorded before and after the 6MWT

Insulin6 weeks, 3 and 6 month post-baseline follow-up

Measured in microUnit/milliliter (McU/mL) of blood.

Hemoglobin A1C6 weeks, 3 and 6 month post-baseline follow-up

Also known as glycated hemoglobin test, and glycohemoglobin. Measured in milligram/deciliter (mg/dL) of blood.

Health Behaviour in School Aged Children (HSBC)- Eating Habits Questionnaire6 weeks

Two multiple choice questions. 1 question assesses the frequency of breakfast consumption during weekdays and weekends. For weekdays- scores range from 1 ("I never have breakfast during weekdays") - 6 ("Five days"). For weekends scores range from 1 ("I never have breakfast during the weekend") to 3 ("I usually have breakfast on both weekend days (Saturday AND Sunday)". The higher the score the better the outcome.

1 question assesses food consumption frequency of fruit, vegetables, sweets and soft drinks that contain sugar.Scores range from 1 ("Never") to 7 ("Every day, more than once"). Higher scores on fruit and vegetables = better outcome. The higher the score on sweets and soft drinks the worse the outcome.

Aspartate aminotransferase (AST)6 weeks, 3 and 6 month post-baseline follow-up

Measured in millimoles Per Litre (mmol/L).

Hip Circumference6 weeks, 3 and 6 month post-baseline follow-up

Maximum perimeter of the hips at the gluteal level in centimeters (cm) using a tape measure.

Waist Circumference6 weeks, 3 and 6 month post-baseline follow-up

Maximum circumference of the horizontal line between the last rib and the superior iliac crest in centimetres (cm) using a tape measure.

Triglycerides6 weeks, 3 and 6 month post-baseline follow-up

Measured in milligram/deciliter (mg/dL) of blood.

Body Mass Index (BMI)- Kg/m26 weeks, 3 and 6 month post-baseline follow-up
HeightBaseline- Week 1

Centimeters (cm)

Trial Locations

Locations (1)

Hospital Infantil de Mexico

🇲🇽

Mexico City, Mexico

© Copyright 2025. All Rights Reserved by MedPath